ArticleNature communications2025
Gut microbial β-glucuronidases and their role in the microbiome-metabolite axis in colorectal cancer.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- β-Glucuronidase at the Microbiota-Host Interface: Dual Regulatory Roles and Precision Modulation by Natural Products.Molecules (Basel, Switzerland) · 2026Review
- Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targets.Gut microbiome (Cambridge, England) · 2026Article
- Gut microbial β-glucuronidases and their role in the microbiome-metabolite axis in colorectal cancer.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) development involves microbial and metabolic dysbiosis, with gut microbial β-glucuronidases (gmGUSs) potentially impacting carcinogenesis through de-glucuronidation of diverse important molecules. Here, we identify 550 gmGUSs from a public cohort, employing 114 alignment references, three structural domains, and seven conserved residues. Stage-specific shifts include enrichment of mini-Loop2 (a category defined by two active site-adjacent loop regions) and species-level gmGUS dysregulation (e.g., Bacteroides cellulosilyticus) in CRC. GUS biomarkers display modest efficacy in classifying CRC and adenoma patients from controls, though with limited generalizability, and in predicting CRC outcomes (AUCs > 0.8). Taxonomic and metabolic association analyses highlight microbe-gmGUS-metabolite (MGM) axis perturbations, including increased Alistipes and Fusobacterium, enriched mucin and flavonoid degraders, as well as amino acid and vitamin metabolism alterations linked to CRC progression. In vitro enzyme assays show that the identified gmGUSs possess differential substrate activities. Furthermore, RNA-seq of HCT116 cells co-cultured with BC.G3 (one of the differential gmGUSs from B. cellulosilyticus) reveals upregulation of RNA transcription, DNA replication, and protein folding, shedding preliminary light on its potential effects in CRC progression. Here, we define disturbance of MGM axis in colorectal tumorigenesis and offer potential early diagnostic biomarkers and therapeutic targets for CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.